Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products

IMPORTANCE: Transmucosal immediate-release fentanyls (TIRFs), indicated solely for breakthrough cancer pain in opioid-tolerant patients, are subject to a US Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategy (REMS) to prevent them from being prescribed inappropriately. OBJECT...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA
Autors principals: Rollman, Jeffrey Eric, Heyward, James, Olson, Lily, Lurie, Peter, Sharfstein, Joshua, Alexander, G. Caleb
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2019
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6439622/
https://ncbi.nlm.nih.gov/pubmed/30778596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2019.0235
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars